The combined use of TDN-IKE and PDIA3 inhibitors exhibits a synergistic antitumor effect against GBM therapy in vivo, providing a potential therapeutic approach for ferroptosis-based therapy in GBM. The gene discussed is PDIA3; the disease is glioblastoma.